Key Highlights

  • OSRH shares fell roughly 29.4% in pre-market trading on August 20, 2026, to $0.2633, extending a decline from a prior close near $0.3731.
  • The drop follows an August 19, 2026 notice from Nasdaq that OSR Health's stock and warrants face delisting from the Nasdaq Capital Market for failing to maintain the $1.00 minimum bid price, with trading suspension set for the open of August 26, 2026.
  • OSR Health says it intends to request a hearing before the Nasdaq Independent Hearings Panel to appeal the determination, though approval of any extension is not guaranteed.
  • The stock saw extraordinary Volume in the days before the notice, trading about 370 million shares on August 17 and 145 million on August 18 as it briefly touched an intraday high of $0.84, roughly 16 cents short of the compliance threshold, before reversing lower.

Delisting Notice Triggers Renewed Sell-Off

OSR Health (NASDAQ:OSRH), a Nasdaq-listed healthcare holding company, saw its shares fall about 29.4% in pre-market trading on August 20, 2026, to $0.2633 from a prior close of roughly $0.3731. The move extends a decline that began in earnest on August 19, when Nasdaq informed the company that its common stock and warrants face delisting from the Nasdaq Capital Market after it failed to regain compliance with the exchange's $1.00 minimum bid price requirement. That announcement alone drove a roughly 13% decline in OSRH shares on August 19, and the stock is falling further as the market absorbs the news that trading is scheduled to be suspended at the open on August 26, 2026.

A Long Fight To Stay Above $1.00

OSR Health first received a Nasdaq non-compliance notice on September 5, 2025, and was granted a standard 180-day period to regain compliance, which lapsed on March 4, 2026. A second 180-day compliance period was set to expire August 31, 2026, but the company needed its stock to close above $1.00 for ten consecutive Business days well before that final deadline. Shares came tantalizingly close on August 18, touching an intraday high of $0.84 -- about 16 cents short, according to CEO Peter Hwang -- amid heavy trading volume that ranked among the highest on the entire Nasdaq exchange that day, before Nasdaq issued its delisting determination.

Appeal Process And Licensing Hopes

OSR Health plans to request a hearing before the Nasdaq Independent Hearings Panel to contest the determination and seek additional time, a process that can pause the delisting but offers no guarantee of a favorable outcome. Management has pointed to inbound interest from potential partners in out-licensing technologies held by two of its subsidiaries, with one described as being at a preliminary term-sheet stage, as a possible catalyst that could support the share price independent of the compliance fight. Until either the hearing panel grants relief or a value-creating deal materializes, the stock remains exposed to further downside and eventual trading suspension risk.

Bottom Line

OSR Health shares are extending a sharp decline after Nasdaq's August 19, 2026 determination that the stock and warrants face delisting for failing the $1.00 minimum bid price test, with trading suspension currently slated for August 26. These are the verified facts as reported. Whether the pullback extends may depend on the outcome of the company's planned Nasdaq Independent Hearings Panel appeal and any progress on the Subsidiary out-licensing talks management has cited as a potential offsetting catalyst.